Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Million)
1.2.1. Peptide Drug Conjugates Market, by Region, 2019-2029 (USD Million)
1.2.2. Peptide Drug Conjugates Market, by Product, 2019-2029 (USD Million)
1.2.3. Peptide Drug Conjugates Market, by Type, 2019-2029 (USD Million)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Peptide Drug Conjugates Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Peptide Drug Conjugates Market Dynamics
3.1. Peptide Drug Conjugates Market Impact Analysis (2019-2029)
3.1.1. Market Drivers
3.1.1.1. Rising incidences of cancer and related mortality
3.1.1.2. Increasing expenditure on clinical trial
3.1.2. Market Challenges
3.1.2.1. Slow clinical development process
3.1.2.2. Major drawback associated with such small molecules
3.1.3. Market Opportunities
3.1.3.1. Strong product pipeline
3.1.3.2. Growing R&D investment
Chapter 4. Global Peptide Drug Conjugates Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Futuristic Approach to Porter’s 5 Force Model (2019-2029)
4.3. PEST Analysis
4.3.1. Political
4.3.2. Economical
4.3.3. Social
4.3.4. Technological
4.4. Top investment opportunity
4.5. Top winning strategies
4.6. Industry Experts Prospective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Risk Assessment: COVID-19 Impact
5.1. Assessment of the overall impact of COVID-19 on the industry
5.2. Pre COVID-19 and post COVID-19 Market scenario
Chapter 6. Global Peptide Drug Conjugates Market, by Product
6.1. Market Snapshot
6.2. Global Peptide Drug Conjugates Market by Product, Performance – Potential Analysis
6.3. Global Peptide Drug Conjugates Market Estimates & Forecasts by Product 2019-2029 (USD Million)
6.4. Peptide Drug Conjugates Market, Sub Segment Analysis
6.4.1. Lutetium
6.4.2. Melflufen
6.4.3. ANG1005
6.4.4. BT1718
6.4.5. CBX-12
6.4.6. Other Pipeline Products
Chapter 7. Global Peptide Drug Conjugates Market, by Type
7.1. Market Snapshot
7.2. Global Peptide Drug Conjugates Market by Type, Performance – Potential Analysis
7.3. Global Peptide Drug Conjugates Market Estimates & Forecasts by Type 2019-2029 (USD Million)
7.4. Peptide Drug Conjugates Market, Sub Segment Analysis
7.4.1. Therapeutic
7.4.2. Diagnostic
Chapter 8. Global Peptide Drug Conjugates Market, Regional Analysis
8.1. Peptide Drug Conjugates Market, Regional Market Snapshot
8.2. North America Peptide Drug Conjugates Market
8.2.1. U.S. Peptide Drug Conjugates Market
8.2.1.1. Product breakdown estimates & forecasts, 2019-2029
8.2.1.2. Type breakdown estimates & forecasts, 2019-2029
8.2.2. Canada Peptide Drug Conjugates Market
8.3. Europe Peptide Drug Conjugates Market Snapshot
8.3.1. U.K. Peptide Drug Conjugates Market
8.3.2. Germany Peptide Drug Conjugates Market
8.3.3. France Peptide Drug Conjugates Market
8.3.4. Spain Peptide Drug Conjugates Market
8.3.5. Italy Peptide Drug Conjugates Market
8.3.6. Rest of Europe Peptide Drug Conjugates Market
8.4. Asia-Pacific Peptide Drug Conjugates Market Snapshot
8.4.1. China Peptide Drug Conjugates Market
8.4.2. India Peptide Drug Conjugates Market
8.4.3. Japan Peptide Drug Conjugates Market
8.4.4. Australia Peptide Drug Conjugates Market
8.4.5. South Korea Peptide Drug Conjugates Market
8.4.6. Rest of Asia Pacific Peptide Drug Conjugates Market
8.5. Latin America Peptide Drug Conjugates Market Snapshot
8.5.1. Brazil Peptide Drug Conjugates Market
8.5.2. Mexico Peptide Drug Conjugates Market
8.5.3. Rest of Latin America Peptide Drug Conjugates Market
8.6. Rest of The World Peptide Drug Conjugates Market
Chapter 9. Competitive Intelligence
9.1. Top Market Strategies
9.2. Company Profiles
9.2.1. Novartis AG
9.2.1.1. Key Information
9.2.1.2. Overview
9.2.1.3. Financial (Subject to Data Availability)
9.2.1.4. Product Summary
9.2.1.5. Recent Developments
9.2.2. Oncopeptides AB
9.2.3. Bicycle Therapeutics
9.2.4. AstraZeneca
9.2.5. Cybrexa Therapeutics
9.2.6. Angiochem Inc.
9.2.7. Innovasium Soricimed Biopharma
9.2.8. Theratechnologies
9.2.9. Pfizer Inc.
9.2.10. Validus Pharmaceuticals LLC
Chapter 10. Research Process
10.1. Research Process
10.1.1. Data Mining
10.1.2. Analysis
10.1.3. Market Estimation
10.1.4. Validation
10.1.5. Publishing
10.2. Research Attributes
10.3. Research Assumption
